173 related articles for article (PubMed ID: 30382527)
1. Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder.
Ahmed MAH; Ali MH; Abbas HH; Elatrash GA; Foda AAM
Pathol Oncol Res; 2020 Jan; 26(1):411-418. PubMed ID: 30382527
[TBL] [Abstract][Full Text] [Related]
2. Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage.
Muller P; Coates PJ; Nenutil R; Trcka F; Hrstka R; Chovanec J; Brychtova V; Vojtesek B
J Ovarian Res; 2019 Mar; 12(1):30. PubMed ID: 30917858
[TBL] [Abstract][Full Text] [Related]
3. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
4. TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome.
Aleskandarany MA; Negm OH; Rakha EA; Ahmed MA; Nolan CC; Ball GR; Caldas C; Green AR; Tighe PJ; Ellis IO
Breast Cancer Res Treat; 2012 Nov; 136(2):419-27. PubMed ID: 23053644
[TBL] [Abstract][Full Text] [Related]
5. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
Samaratunga H; Khoo K
Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
[TBL] [Abstract][Full Text] [Related]
6. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
7. Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival.
Li G; Yu J; Song H; Zhu S; Sun L; Shang Z; Niu Y
BMC Cancer; 2017 Aug; 17(1):530. PubMed ID: 28789622
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of NANOG in urothelial carcinoma of the bladder.
Md Akhir MKA; Hussin H; Veerakumarasivam A; Choy CS; Abdullah MA; Abd Ghani F
Malays J Pathol; 2017 Dec; 39(3):227-234. PubMed ID: 29279584
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD
Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713
[TBL] [Abstract][Full Text] [Related]
11. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.
Hodgson A; Xu B; Downes MR
Histopathology; 2017 Aug; 71(2):296-304. PubMed ID: 28342221
[TBL] [Abstract][Full Text] [Related]
12. Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder.
Hodgson A; Xu B; Satkunasivam R; Downes MR
J Clin Pathol; 2018 Feb; 71(2):154-160. PubMed ID: 28768702
[TBL] [Abstract][Full Text] [Related]
13. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
May M; Helke C; Nitzke T; Vogler H; Hoschke B
Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
[TBL] [Abstract][Full Text] [Related]
14. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion.
Garg M; Kanojia D; Seth A; Kumar R; Gupta A; Surolia A; Suri A
Eur J Cancer; 2010 Jan; 46(1):207-15. PubMed ID: 19914824
[TBL] [Abstract][Full Text] [Related]
15. Immunoprofile-based subgrouping of urothelial bladder carcinomas for survival prediction.
Kim K; Sung CO; Park BH; Ku JY; Go H; Ro JY; Kim J; Cho YM
Hum Pathol; 2015 Oct; 46(10):1464-70. PubMed ID: 26232864
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.
Rabien A; Ratert N; Högner A; Erbersdobler A; Jung K; Ecke TH; Kilic E
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29857476
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
18. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of semaphorin 3A in patients with urothelial cancer.
Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
[TBL] [Abstract][Full Text] [Related]
20. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF
J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
